BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28289041)

  • 1. Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.
    Hollander P; Bays HE; Rosenstock J; Frustaci ME; Fung A; Vercruysse F; Erondu N
    Diabetes Care; 2017 May; 40(5):632-639. PubMed ID: 28289041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
    Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.
    Bays HE; Weinstein R; Law G; Canovatchel W
    Obesity (Silver Spring); 2014 Apr; 22(4):1042-9. PubMed ID: 24227660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
    Aronne LJ; Halseth AE; Burns CM; Miller S; Shen LZ
    Obesity (Silver Spring); 2010 Sep; 18(9):1739-46. PubMed ID: 20094043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
    Davidson MH; Tonstad S; Oparil S; Schwiers M; Day WW; Bowden CH
    Am J Cardiol; 2013 Apr; 111(8):1131-8. PubMed ID: 23375187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phentermine/topiramate for the treatment of obesity.
    Smith SM; Meyer M; Trinkley KE
    Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
    Winslow DH; Bowden CH; DiDonato KP; McCullough PA
    Sleep; 2012 Nov; 35(11):1529-39. PubMed ID: 23115402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people.
    Kim KK; Cho HJ; Kang HC; Youn BB; Lee KR
    Yonsei Med J; 2006 Oct; 47(5):614-25. PubMed ID: 17066505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Lavalle-González FJ; Eliaschewitz FG; Cerdas S; Chacon Mdel P; Tong C; Alba M
    Curr Med Res Opin; 2016; 32(3):427-39. PubMed ID: 26579834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B
    Digenio A; Pham NC; Watts LM; Morgan ES; Jung SW; Baker BF; Geary RS; Bhanot S
    Diabetes Care; 2018 Apr; 41(4):807-814. PubMed ID: 29439147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
    Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
    Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
    Guo F; Garvey WT
    Diabetes Care; 2017 Jul; 40(7):856-862. PubMed ID: 28455281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
    Whigham LD; Dhurandhar NV; Rahko PS; Atkinson RL
    Int J Obes (Lond); 2007 May; 31(5):850-7. PubMed ID: 17146452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.